<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioinvent International Ab — News on 6ix</title>
<link>https://6ix.com/company/bioinvent-international-ab-1</link>
<description>Latest news and press releases for Bioinvent International Ab on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 06:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioinvent-international-ab-1" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d563ecbeedb30cb6f80376.webp</url>
<title>Bioinvent International Ab</title>
<link>https://6ix.com/company/bioinvent-international-ab-1</link>
</image>
<item>
<title>BioInvent International AB: Interim Report January - March 2026</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-interim-report-january-march-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-interim-report-january-march-2026</guid>
<pubDate>Wed, 29 Apr 2026 06:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV) "During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), ...</description>
</item>
<item>
<title>BioInvent International AB Publishes Annual Report 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-publishes-annual-report-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-publishes-annual-report-2025</guid>
<pubDate>Tue, 31 Mar 2026 10:05:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / March 31, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, ...</description>
</item>
<item>
<title>BioInvent Achieves Phase 3 Milestone for HMI-115 in Endometriosis</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-achieves-phase-3-milestone-for-hmi-115-in-endometriosis</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-achieves-phase-3-milestone-for-hmi-115-in-endometriosis</guid>
<pubDate>Thu, 26 Mar 2026 14:44:00 GMT</pubDate>
<description>BioInvent International (STO:BINV) - Achievement of the milestone triggers a payment of € 1 million LUND, SE / ACCESS Newswire / March 26, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel ...</description>
</item>
<item>
<title>Notice to Annual General Meeting in BioInvent International AB</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/notice-to-annual-general-meeting-in-bioinvent-international-ab-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/notice-to-annual-general-meeting-in-bioinvent-international-ab-1</guid>
<pubDate>Tue, 24 Mar 2026 07:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / March 24, 2026 / BioInvent International (STO:BINV) - The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m. CEST, 29 ...</description>
</item>
<item>
<title>BioInvent International AB: Year-End Report January 1 - December 31, 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-year-end-report-january-1-december-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-year-end-report-january-1-december-31-2025</guid>
<pubDate>Thu, 26 Feb 2026 07:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / February 26, 2026 / BioInvent International (STO:BINV) - "During 2025 we sharpened our clinical focus and resource allocation to accelerate our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcγRIIB), while ...</description>
</item>
<item>
<title>Invitation to Presentation of BioInvent's Year-End Report 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/invitation-to-presentation-of-bioinvents-year-end-report-2025</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/invitation-to-presentation-of-bioinvents-year-end-report-2025</guid>
<pubDate>Thu, 26 Feb 2026 06:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / February 26, 2026 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the Year-end report 2025 on February 26 at 2:00 pm CET. The report will ...</description>
</item>
<item>
<title>BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-nomination-of-two-new-board-members-ahead-of-2026-annual-general-meeting-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-nomination-of-two-new-board-members-ahead-of-2026-annual-general-meeting-1</guid>
<pubDate>Mon, 23 Feb 2026 09:15:00 GMT</pubDate>
<description>Kate Hermans: Global life sciences executive with 25+ years of leadership across biopharma, commercial strategy, global operations, and value-creation transformations in both public and venture-backed companies Scott Zinober: Senior investment professional ...</description>
</item>
<item>
<title>BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA(R) (pembrolizumab) in Recurrent Ovarian Cancer</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-reports-promising-data-from-ongoing-phase-2a-study-for-bi-1808-with-keytrudar-pembrolizumab-in-recurrent-ovarian-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-reports-promising-data-from-ongoing-phase-2a-study-for-bi-1808-with-keytrudar-pembrolizumab-in-recurrent-ovarian-cancer-1</guid>
<pubDate>Mon, 05 Jan 2026 06:45:00 GMT</pubDate>
<description>24% ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ovarian cancer (8% ORR in KEYNOTE-100) The combination demonstrated a favorable safety and tolerability profile Results ...</description>
</item>
<item>
<title>BioInvent Announces Publication of Preclinical and Early Phase 1 Data for BI-1607 in HER2-Positive Advanced Solid Tumors</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-publication-of-preclinical-and-early-phase-1-data-for-bi-1607-in-her2-positive-advanced-solid-tumors-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-publication-of-preclinical-and-early-phase-1-data-for-bi-1607-in-her2-positive-advanced-solid-tumors-1</guid>
<pubDate>Tue, 18 Nov 2025 13:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 18, 2025 / BioInvent International (STO:BINV): Most (78%) patients experienced disease control (stable disease), including heavily pretreated individuals with HER2-positive breast and gastric cancers A favorable ...</description>
</item>
<item>
<title>EMA Positive Opinion for Orphan Drug Designation to BioInvent's BI‑1808 for the Treatment of Cutaneous T-cell Lymphoma</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/ema-positive-opinion-for-orphan-drug-designation-to-bioinvents-bi1808-for-the-treatment-of-cutaneous-t-cell-lymphoma-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/ema-positive-opinion-for-orphan-drug-designation-to-bioinvents-bi1808-for-the-treatment-of-cutaneous-t-cell-lymphoma-1</guid>
<pubDate>Mon, 17 Nov 2025 08:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / November 17, 2025 /BioInvent International AB ("BioInvent")(Nasdaq Stockholm: BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...</description>
</item>
<item>
<title>BioInvent International AB: Interim Report January - September 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-interim-report-january-september-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-interim-report-january-september-2025-1</guid>
<pubDate>Wed, 29 Oct 2025 07:20:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 29, 2025 / BioInvent International (STO:BINV) "The third quarter of 2025 marked continued momentum for BioInvent as we decided to focus on our most advanced programs BI-1206 and BI-1808. This strategic direction ...</description>
</item>
<item>
<title>Invitation to Presentation of BioInvent's Interim Report January - September 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/invitation-to-presentation-of-bioinvents-interim-report-january-september-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/invitation-to-presentation-of-bioinvents-interim-report-january-september-2025-1</guid>
<pubDate>Mon, 27 Oct 2025 14:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 27, 2025 /BioInvent International AB ("BioInvent")(Nasdaq Stockholm:BINV)(STO:BINV) invites investors, analysts and the press to a presentation of the interim report January - September 2025 at 2:00 pm CET on Wednesday ...</description>
</item>
<item>
<title>BioInvent Announces Initiation of BI-1206 Phase 2a Trial in Advanced or Metastatic NSCLC and Uveal Melanoma</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-initiation-of-bi-1206-phase-2a-trial-in-advanced-or-metastatic-nsclc-and-uveal-melanoma-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-initiation-of-bi-1206-phase-2a-trial-in-advanced-or-metastatic-nsclc-and-uveal-melanoma-1</guid>
<pubDate>Wed, 08 Oct 2025 06:15:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / October 8, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer ...</description>
</item>
<item>
<title>BioInvent Announces Board of Directors Update</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-board-of-directors-update-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-board-of-directors-update-1</guid>
<pubDate>Tue, 02 Sep 2025 08:30:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / September 2, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, ...</description>
</item>
<item>
<title>BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical Programs and Enhance Value Creation</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-strategic-changes-in-portfolio-to-accelerate-lead-clinical-programs-and-enhance-value-creation-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-strategic-changes-in-portfolio-to-accelerate-lead-clinical-programs-and-enhance-value-creation-1</guid>
<pubDate>Tue, 26 Aug 2025 06:50:00 GMT</pubDate>
<description>Focusing on lead programs BI-1206 and BI-1808, with strong clinical data and upcoming value-creation milestones Phase 2a study of BI-1206 in combination with pembrolizumab in first-line NSCLC to initiate in H2 2025 LUND, SE / ACCESS Newswire / August ...</description>
</item>
<item>
<title>BioInvent International AB: Interim Report January - June 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-interim-report-january-june-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-international-ab-interim-report-january-june-2025-1</guid>
<pubDate>Tue, 26 Aug 2025 06:50:00 GMT</pubDate>
<description>LUND, SE / ACCESS Newswire / August 26, 2025 /BioInvent International (STO:BINV) - "This is an important next step for BioInvent," said Martin Welschof, Chief Executive Officer of BioInvent. "We are sharpening our clinical focus on our most advanced ...</description>
</item>
<item>
<title>BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-promising-phase-1-data-of-bi-1206-in-combination-with-keytrudar-pembrolizumab-in-solid-tumors-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-promising-phase-1-data-of-bi-1206-in-combination-with-keytrudar-pembrolizumab-in-solid-tumors-1</guid>
<pubDate>Wed, 11 Jun 2025 06:20:00 GMT</pubDate>
<description>The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 patients with stable disease. Based on this promising ...</description>
</item>
<item>
<title>XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/xoma-royalty-purchases-mezagitamab-royalty-and-milestone-rights-held-by-bioinvent-international-for-up-to-usd-dollar30-million-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/xoma-royalty-purchases-mezagitamab-royalty-and-milestone-rights-held-by-bioinvent-international-for-up-to-usd-dollar30-million-1</guid>
<pubDate>Tue, 27 May 2025 12:01:00 GMT</pubDate>
<description>EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 millio</description>
</item>
<item>
<title>BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-updated-phase-2a-triple-combination-arm-data-of-bi-1206-rituximab-and-calquence-for-the-treatment-of-non-hodgkins-lymphoma-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/bioinvent-announces-updated-phase-2a-triple-combination-arm-data-of-bi-1206-rituximab-and-calquence-for-the-treatment-of-non-hodgkins-lymphoma-1</guid>
<pubDate>Wed, 14 May 2025 13:40:00 GMT</pubDate>
<description>Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical response in the first eight patients evaluated Results ...</description>
</item>
<item>
<title>Resolutions at BioInvent's Annual General Meeting 2025</title>
<link>https://6ix.com/company/bioinvent-international-ab-1/news/resolutions-at-bioinvents-annual-general-meeting-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioinvent-international-ab-1/news/resolutions-at-bioinvents-annual-general-meeting-2025-1</guid>
<pubDate>Tue, 29 Apr 2025 15:15:00 GMT</pubDate>
<description>LUND, SWEDEN / ACCESS Newswire / April 29, 2025 / The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard ...</description>
</item>
</channel>
</rss>